Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2026)

Royalty Pharma has reported Cash & Equivalents for 8 years, with the latest figure at $586.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 46.09% year-over-year to $586.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $586.4 million (down 46.09% YoY) and the FY2025 annual result came in at $618.7 million, down 33.4% from the prior year.
• Cash & Equivalents declined to $586.4 million in Q1 2026 per RPRX's latest filing, from $618.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $2.2 billion in Q2 2023 and troughed at $477.0 million in Q4 2023.
• A 5-year average of $1.2 billion and a median of $950.1 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 152.75% in 2022, then sank 72.12% in 2023.
• Over 5 years, Cash & Equivalents stood at $1.7 billion in 2022, then tumbled by 72.12% to $477.0 million in 2023, then surged by 94.76% to $929.0 million in 2024, then plunged by 33.4% to $618.7 million in 2025, then decreased by 5.22% to $586.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $586.4 million, $618.7 million, and $938.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.